๐ฐ Practice Guidelines News
Page 40 - Practice Guidelines News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Practice Guidelines. Real-time updates on events, politics, business and more.
May 23, 2022
The National Comprehensive Cancer Network today announced the recipients of 2022 awards for both internal and external champions advancing NCCN's mission and helping all people with cancer to live better lives.
May 22, 2022
People should look out for eight signs of acute encephalitis in children and seek emergency medical treatment if they occur, the Central Epidemic Command Center (CECC) said yesterday. The symptoms are a body temperature of at least 41ยฐC, impaired consciousness, excessive sleepiness, a persistent headache, vomiting, involuntary muscle twitching (myoclonic jerks), convulsions and an unsteady gait, said Centers for Disease Control Deputy Director-General Philip Lo (็พ
ไธ้), deputy head of the C...
May 19, 2022
Salt Lake City UT (PRWEB) May 19, 2022 -- The Center for Genomic Interpretation (CGI) continues hosting its cutting-edge Rising Tide Podcast series, which
May 12, 2022
Sensitivity analysis shows after-tax NPV 10% of US$914 Million at US$4,200/t HPMSM Montreal, Quebec--(Newsfile Corp. - May 12, 2022) - Manganese X Energy Corp. (TSXV: MN) (FSE: 9SC) (OTCQB: MNXXF) ("Manganese
May 11, 2022
A new China document provides more clarity on the requirements for MNCs to engage in cross-border personal information processing. Here's what to know.
May 11, 2022
/PRNewswire/ -- New research in the May 2022 issue of JNCCNโJournal of the National Comprehensive Cancer Network finds the inclusion of the smoking cessation...
May 6, 2022
BIS Research Study Highlights the Next-Generation Gynecological Cancer Diagnostics Market to Reach $5.66 billion by 2031
May 5, 2022
Halifax, Nova Scotia--(Newsfile Corp. - May 5, 2022) - John F. Wightman, M.Sc. P.Eng., President & CEO of Champlain Mineral Ventures Ltd. ("Champlain" or the "Company") is pleased to announce the completion
May 4, 2022
With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for postmenopausal
May 4, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients